NMN Shields Aging Hearts from High-Fat Diet Damage via Mitophagy Pathway
NMN activates the Sirt3/PINK1/Parkin pathway to reduce cardiac fibrosis, senescence, and inflammation in aging mice fed a high-fat diet.
Summary
Researchers found that nicotinamide mononucleotide (NMN) protects aging mouse hearts from high-fat diet-induced damage by activating the Sirt3/PINK1/Parkin signaling pathway. In a 7-month study, aging male mice on a high-fat diet supplemented with NMN showed reduced heart enlargement, less myocardial fibrosis, lower levels of cellular senescence markers, reduced inflammation, and decreased apoptosis compared to unsupplemented high-fat diet mice. NMN also restored impaired autophagy flux in both heart tissue and lab-grown cardiomyocytes exposed to fatty acids. Blocking Sirt3 eliminated these protective effects, confirming it as the critical upstream regulator. The findings position NMN as a candidate therapy for metabolic cardiomyopathy in aging populations.
Detailed Summary
Metabolic cardiomyopathy — heart damage driven by obesity and poor diet — is increasingly common in aging populations and remains difficult to treat. Long-term high-fat diet consumption accelerates cardiac aging through inflammation, cellular senescence, fibrosis, and impaired cellular cleanup mechanisms. NMN, a direct precursor to NAD+, has emerged as a molecule of significant interest in aging research, but its specific cardiac-protective mechanisms were poorly understood.
This study used 14-month-old male C57BL/6J mice — an age approximating middle-to-older adulthood — divided into normal diet, high-fat diet (HFD), and HFD plus NMN groups. NMN was delivered via drinking water at 400 mg/kg for 7 months. Cardiac tissue was analyzed with multiple techniques including Western blotting and staining methods, while H9c2 cardiomyocyte cell cultures exposed to palmitic acid provided a complementary in vitro lipotoxicity model.
NMN treatment produced striking improvements across multiple cardiac health markers. It reduced heart enlargement and myocardial fibrosis, lowered senescence-associated secretory phenotype (SASP) markers including Serpine1, MMP3, and p16, and decreased senescence indicators p21 and beta-galactosidase. Pro-inflammatory cytokines IL-1β and TNF-α fell significantly while anti-inflammatory IL-10 rose. Apoptosis markers including the Bax/Bcl-2 ratio and cleaved caspase-3 were also reduced. Crucially, NMN upregulated Sirt3, PINK1, and Parkin proteins and improved autophagy-lysosomal function as evidenced by enhanced LC3-II/LC3-I ratios, increased TFEB, and decreased p62. In cell culture, these benefits were abolished when Sirt3 was selectively inhibited, confirming the pathway's necessity.
These findings suggest NMN may combat metabolic cardiomyopathy through a coordinated mechanism: boosting NAD+ activates Sirt3, which triggers PINK1/Parkin-mediated mitophagy to clear damaged mitochondria and reduce the downstream cascade of inflammation, senescence, and cell death.
Important caveats apply. This is an animal study, and translation to humans requires clinical trials. The mouse aging model, while relevant, may not fully replicate human metabolic cardiomyopathy. Additionally, optimal NMN dosing for humans remains undefined.
Key Findings
- NMN reduced myocardial fibrosis and heart enlargement in aging mice on a high-fat diet after 7 months of supplementation.
- NMN significantly lowered senescence markers (p21, β-gal) and SASP components including Serpine1, MMP3, and p16.
- Pro-inflammatory cytokines IL-1β and TNF-α decreased while anti-inflammatory IL-10 increased in cardiac tissue with NMN.
- NMN activated the Sirt3/PINK1/Parkin pathway and restored impaired autophagy flux; benefits were lost when Sirt3 was blocked.
- In vitro, NMN protected H9c2 cardiomyocytes from palmitic acid-induced cytotoxicity and autophagy impairment.
Methodology
Male C57BL/6J mice aged 14 months were assigned to normal diet, high-fat diet, or high-fat diet plus NMN (400 mg/kg in drinking water) groups for 7 months, with cardiac tissue assessed via histology, Western blot, qRT-PCR, and immunohistochemistry. In vitro experiments used palmitic acid-treated H9c2 cardiomyocytes with autophagy flux measured by mRFP-GFP-LC3 adenoviral transfection. Sirt3 inhibitor 3-TYP was used to confirm pathway dependency.
Study Limitations
This is a mouse study and results may not directly translate to human cardiac physiology or metabolic disease progression. The study used only male mice, limiting generalizability across sexes. Human-equivalent dosing and long-term safety of NMN supplementation in older cardiac patients remain to be established in clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: